On May 9, 2025, a tragic call for change in Canada’s cancer treatment approach was made by Brian Armit to Ontario Premier Doug Ford. This call was initiated during a family trip to Winnipeg, where they were attending a Winnipeg Jets playoff game. Brian’s son, Evan, battled melanoma and needed access to an urgent treatment.
Tragic Case Highlights Need for Change
Evan Armit was only 22 when his family sought help for a life-threatening condition. His last hope lay in a revolutionary treatment called tumour-infiltrating lymphocyte (TIL) therapy, which was approved in the United States but still under review in Canada. The estimated cost for this treatment at a Boston hospital was between $750,000 and $1 million. Despite the family’s efforts and support from medical professionals, Ontario’s health insurance plan, OHIP, denied coverage for the treatment twice.
In a desperate measure, Brian contacted Premier Ford, hoping for advocacy from the provincial government. Although Ford personally returned his call, the outcome was unfortunately disappointing. The provincial officials advised the Armit family to file an appeal, which ultimately failed on August 28, 2025, just days after Evan passed away at the age of 23. The tragedy unfolded just nine days after Health Canada approved TIL therapy.
Challenges Within Canada’s Cancer Treatment System
This incident brought to light longstanding issues within Canada’s cancer treatment system. A significant gap exists, averaging 2½ years, between when new cancer medications receive approval in the United States and when they become publicly funded in Canada. Although the Special Access Program (SAP) allows for out-of-country access to unapproved drugs, it does not suit individualized treatments like TIL therapy.
TIL therapy relies on a patient’s own cells, extracted and multiplied in laboratory settings to enhance effectiveness against cancer. The specific TIL treatment Evan sought, lifileucel, costs approximately $515,000. Due to classification issues, the Ontario Health Services Appeal and Review Board rejected his appeal, maintaining that OHIP’s mechanisms were not designed for treatments still under regulatory review.
Statistics and Spending Trends in Ontario Healthcare
| Year | Out-of-Country Health Services Spending | Number of Applications | Approval Rate |
|---|---|---|---|
| 2020-2021 | $32.4 million | 748 | ~77% |
| 2024-2025 | $46.8 million | 1,027 | ~77% |
The Ontario government allocated $46.8 million for out-of-country health services in 2024-2025, a notable increase from previous years. Meanwhile, the approval rate for applications remained steady at about 77 percent. However, Ontario’s Ministry of Health responded to queries related to Evan’s case without offering specific insights, indicating that unapproved therapies would not receive independent funding.
Advocating for Change in Cancer Treatment Policies
Evan’s parents share their story in hopes of prompting change in how provinces address urgent cancer treatments unavailable in Canada. They ask for greater flexibility regarding coverage for necessary therapies from the U.S., especially when time is of the essence. The need for reform in the provincial health care system is more pronounced than ever, as expressed by Brian Armit, who maintained that their family believed Evan deserved access to timely and effective treatment.
Evan’s initial symptoms began in 2024 when he discovered a suspicious lesion. After undergoing treatment, he believed his cancer was under control. It wasn’t until severe headaches arose that the seriousness of his condition was revealed. Despite this, his positivity throughout his treatments left a lasting impression on those around him.
The Armit family’s experience underscores an urgent call for change within Canada’s healthcare system, emphasizing the need for preemptive adjustments in cancer treatment policies. The hope is that future patients may not suffer delays in accessing critical therapies that could save their lives.
